Improved Survival After Concurrent Weekly Cisplatin and Radiotherapy for Cervical Carcinoma with Assessment of Acute and Late Side-effects

Weekly cisplatin 40 mg/m2 concurrent with radiotherapy is well tolerated when given to an unselected population of patients. Survival rates seem to be excellent, with both local control and overall survival being at least as good as those in published randomised trials.